Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1-9. (Canceled without prejudice).

10. (Previously presented) A compound having the formula:



wherein:

R^1 is H, $(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $C(O)R^3$, $C(S)R^3$, $C(O)OR^4$, $(C_1–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $C(O)NHR^3$, $C(S)NHR^3$, $C(O)NR^3R^{3'}$, $C(S)NR^3R^{3'}$ or $(C_1–C_8)$alkyl–$O(CO)R^5$;

R^2 is H or $(C_1–C_8)$alkyl;

R^3 and $R^{3'}$ are independently $(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $(C_0–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $(C_1–C_8)$alkyl–$O(CO)R^5$, or $C(O)OR^5$;

R^4 is $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, $(C_1–C_4)$alkyl–OR^5, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, or $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl;

R^5 is $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, or $(C_2–C_5)$heteroaryl;

each occurrence of R^6 is independently H, $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_2–C_5)$heteroaryl, or $(C_0–C_8)$alkyl–$C(O)O–R^5$ or the R^6 groups can join to form a heterocycloalkyl group; and

the * represents a chiral-carbon center.

11. (Original) A compound of claim 10, wherein R^1 is H, $(C_1$-$C_4)$alkyl, CH_2OCH_3, $CH_2CH_2OCH_3$, or



wherein Q is O or S, and each occurrence of R^7 is independently H,$(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, halogen, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $(C_0–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $(C_1–C_8)$alkyl–$O(CO)R^5$, or $C(O)OR^5$, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

12. (Original) A compound of claim 10, wherein R^1 is $C(O)R^3$.

13. (Original) A compound of claim 10, wherein R^1 is $C(O)OR^4$.

14. (Previously presented) A compound having the formula:



wherein:

R^1 is H, $(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $C(O)R^3$, $C(S)R^3$, $C(O)OR^4$, $(C_1–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $C(O)NHR^3$, $C(S)NHR^3$, $C(O)NR^3R^{3'}$, $C(S)NR^3R^{3'}$ or $(C_1–C_8)$alkyl–$O(CO)R^5$;

R^2 is H or $(C_1–C_8)$alkyl;

R^3 and $R^{3'}$ are independently $(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $(C_0–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $(C_1–C_8)$alkyl–$O(CO)R^5$, or $C(O)OR^5$;

R^4 is $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, $(C_1–C_4)$alkyl–OR^5, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, or $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl;
R^5 is $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, or $(C_2–C_5)$heteroaryl;
each occurrence of R^6 is independently H, $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_2–C_5)$heteroaryl, or $(C_0–C_8)$alkyl–C(O)O–R^5 or the R^6 groups can join to form a heterocycloalkyl group; and
the * represents a chiral-carbon center.

15. (Original) A compound of claim 14, wherein R^1 is H, $(C_1$-$C_4)$alkyl, CH_2OCH_3, $CH_2CH_2OCH_3$, or



wherein Q is O or S, and each occurrence of R^7 is independently H,$(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, halogen, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $(C_0–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–C(O)OR^5, $(C_1–C_8)$alkyl–O(CO)R^5, or C(O)OR^5, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

16. (Original) A compound of claim 14, wherein R^1 is C(O)R^3.

17. (Original) A compound of claim 14, wherein R^1 is C(O)OR^4.

18. (Previously presented) A compound having the formula:



wherein:

R^1 is H, $(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $C(O)R^3$, $C(S)R^3$, $C(O)OR^4$, $(C_1–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $C(O)NHR^3$, $C(S)NHR^3$, $C(O)NR^3R^{3'}$, $C(S)NR^3R^{3'}$ or $(C_1–C_8)$alkyl–$O(CO)R^5$;

R^2 is H or $(C_1–C_8)$alkyl;

R^3 and $R^{3'}$ are independently $(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $(C_0–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $(C_1–C_8)$alkyl–$O(CO)R^5$, or $C(O)OR^5$;

R^4 is $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, $(C_1–C_4)$alkyl–OR^5, benzyl, aryl, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, or $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl;

R^5 is $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, or $(C_2–C_5)$heteroaryl;

each occurrence of R^6 is independently H, $(C_1–C_8)$alkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, $(C_2–C_5)$heteroaryl, or $(C_0–C_8)$alkyl–$C(O)O–R^5$ or the R^6 groups can join to form a heterocycloalkyl group; and

the * represents a chiral-carbon center.

19. (Original) A compound of claim 18, wherein R^1 is H, $(C_1$-$C_4)$alkyl, CH_2OCH_3, $CH_2CH_2OCH_3$ or



wherein Q is O or S, and each occurrence of R^7 is independently H,$(C_1–C_8)$alkyl, $(C_3–C_7)$cycloalkyl, $(C_2–C_8)$alkenyl, $(C_2–C_8)$alkynyl, benzyl, aryl, halogen, $(C_0–C_4)$alkyl–$(C_1–C_6)$heterocycloalkyl, $(C_0–C_4)$alkyl–$(C_2–C_5)$heteroaryl, $(C_0–C_8)$alkyl–$N(R^6)_2$, $(C_1–C_8)$alkyl–OR^5, $(C_1–C_8)$alkyl–$C(O)OR^5$, $(C_1–C_8)$alkyl–$O(CO)R^5$, or $C(O)OR^5$, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

20. (Original) A compound of claim 18, wherein R^1 is $C(O)R^3$.

21. (Original) A compound of claim 18, wherein R^1 is $C(O)OR^4$.

22-100. (Canceled without prejudice).

101. (New) A compound of claim 10, which is: N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-duhydro-1H-isoindol-4-yl-methyl]-acetamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}cyclopropyl-carboxamide; 1-tert-butyl-3-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-urea; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-3,3-dimethylbutanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-propanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-3-pyridylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}heptanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2-furylcarboxamide; 2-amino-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}acetamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2-thienylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoindolin-4yl]methyl}(ethylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}butanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2-pyridylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}undecamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}2-methylpropanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}cyclopentylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl} cyclohexylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(butylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(propylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}[(methylethylamino)] carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(octylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(cyclopropylamino)carboxamide; or N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(diethylamino)carboxamide.

102. (New) A compound of claim 10, which is: [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl-methyl]-carbamic acid tert-butyl ester; 4-

(aminomethyl)-2-(2,6-dioxo(3-Piperidyl))-isoindoline-1,3-dione; [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl-methyl]-carbamic acid ethyl ester; [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl-methyl]-carbamic acid benzyl ester; 2-(dimethylamino)-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}acetamide; ethyl 6-(3N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}carbamoyl)hexanoate; 3-[(tert-butoxy)carbonylaminol-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}propanamide; 3-amino-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}propanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2-methoxyacetamide; (N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}carbamoyl)methyl acetate; ethyl 2-[N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}carbamoyl)amino]acetate; 7-amino-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}heptanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}benzamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}phenylacetamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(phenylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(benzylamino)carboxamide, 2-(2,6-dioxo-piperidin-3-yl)-4-{[(furan-2-ylmethyl)-amino-methyl}-isoindole-1,3-dione; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-isonicotinamide; 2-(2,6-dioxo(3-piperidyl))-4-({[(cyclohexylamino)thioxomethyl]amino}methyl)isoindole-1,3-dione; 2-(2,6-dioxo(3-piperidyl))-4-({[(ethylamino)thioxomethyl]amino}methyl)isoindole-1,3-dione; 2-(2,6-dioxo(3-piperidyl))-4-({[(propylamino)thioxomethyl]amino}methyl)isoindole-1,3-dione; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(cyclopentylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(3-pyridylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}piperidylcarboxamide; or piperazine-1-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide.

103. (New) A compound of claim 14, which is: N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide; N-{[2-(2,6-dioxo(3-piperidyl))-1-oxoisoindolin-4-yl]methyl}cyclopropylcarboxamide; or N-{[2-(2,6-dioxo(3-piperidyl))-1-oxoisoindolin-4-yl]methyl}(ethylamino)carboxamide.

104. (New) A stereoisomer of a compound of any one of claims 10, 14, 18, 101, 102, or 103.

105. (New) A racemate of a compound of any one of claims 10, 14, 18, 101, 102, or 103.

No fee is believed to be due for this submission. However, should any fees be required for the submission of this paper, or to avoid abandonment of this application, please charge such fees to Jones Day Deposit Account No. 503013.

Respectfully Submitted,

Date: January 19, 2005

45,479
Max Bachrach (Reg. No.)
Jones Day
51 Louisiana Avenue, N.W.
Washington, DC 20001-2113
(202) 879-3939

For: Anthony M. Insogna (Reg. No. 35,203)
Jones Day
12750 High Bluff Drive, Suite 300
San Diego, CA 92130
(858) 314-1200